GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Feb 24, 2023 • 9:00 EST | Read More
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
Feb 2, 2023 • 9:46 EST | Read More